FRLN · Freeline Therapeutics
Acquired Company
Syncona acquired Freeline Therapeutics Holdings plc by way of a scheme of arrangement, with the scheme becoming effective on February 20, 2024 and Freeline’s entire issued share capital now owned or controlled by Syncona Portfolio Limited.
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops vector-mediated adeno-associated virus (AAV) transforming gene therapies for patients suffering from inherited systemic debilitating diseases. The company is headquartered in Stevenage, the United Kingdom.
Market Cap
28.24M
52 Wk Range
$0.00 - $0.00
Previous Close
$6.48
Open
$6.48
Volume
N/A
Day Range
$6.48 - $6.48
Enterprise Value
N/A
Cash
29.45M
Avg Qtr Burn
-8.673M
Insider Ownership
1.10%
Institutional Own.
45.88%
Qtr Updated
Sep 30th 2023